Autoimmune Hepatitis after Ten Years from Pegylated Interferon Treatment- A Case Report

Article Information

Elia C*, Boano V, Battaglia E, Grassini M

Ospedale Cardinal Massaia, Asti, Italy

*Corresponding Author: Dr. Chiara Elia, Ospedale Cardinal Massaia, Asti, Italy

Received: 23 May 2020; Accepted: 08June 2020; Published: 10 July 2020

Citation: Elia C, Boano V, Battaglia E, Grassini M. Autoimmune Hepatitis after Ten Years from Pegylated Interferon Treatment- A Case Report. Archives of Clinical and Medical Case Reports 4 (2020): 668-670.

View / Download Pdf Share at Facebook

Abstract

Interferon is an effective therapy in several diseases; it was a milestone of hepatitis c treatment for a long time. Pegylated interferon is more effective than alpha interferon, adding polyethylene glycol. It has an immunomodulatory effect through the antiviral and cellular activity, but it is burden with adverse effects, some of them are serious. It can be explain with the immunological role of interferon and it is derived in the genesis of some disease like autoimmune hepatitis, it is a liver disease with a multifactorial genesis, an environment agent can stimulate the predisposed subject. We present a case of autoimmune hepatitis ten years later than pegylated interferon therapy.

Keywords

Autoimmune hepatitis; Hepatitis c; Interferon; Pegylated interferon; Pathogenesis

Autoimmune hepatitis articles, Hepatitis c articles, Interferon articles, egylated interferon articles, Pathogenesis articles

Autoimmune hepatitis articles Autoimmune hepatitis Research articles Autoimmune hepatitis review articles Autoimmune hepatitis PubMed articles Autoimmune hepatitis PubMed Central articles Autoimmune hepatitis 2023 articles Autoimmune hepatitis 2024 articles Autoimmune hepatitis Scopus articles Autoimmune hepatitis impact factor journals Autoimmune hepatitis Scopus journals Autoimmune hepatitis PubMed journals Autoimmune hepatitis medical journals Autoimmune hepatitis free journals Autoimmune hepatitis best journals Autoimmune hepatitis top journals Autoimmune hepatitis free medical journals Autoimmune hepatitis famous journals Autoimmune hepatitis Google Scholar indexed journals Hepatitis c articles Hepatitis c Research articles Hepatitis c review articles Hepatitis c PubMed articles Hepatitis c PubMed Central articles Hepatitis c 2023 articles Hepatitis c 2024 articles Hepatitis c Scopus articles Hepatitis c impact factor journals Hepatitis c Scopus journals Hepatitis c PubMed journals Hepatitis c medical journals Hepatitis c free journals Hepatitis c best journals Hepatitis c top journals Hepatitis c free medical journals Hepatitis c famous journals Hepatitis c Google Scholar indexed journals Interferon articles Interferon Research articles Interferon review articles Interferon PubMed articles Interferon PubMed Central articles Interferon 2023 articles Interferon 2024 articles Interferon Scopus articles Interferon impact factor journals Interferon Scopus journals Interferon PubMed journals Interferon medical journals Interferon free journals Interferon best journals Interferon top journals Interferon free medical journals Interferon famous journals Interferon Google Scholar indexed journals Pegylated interferon articles Pegylated interferon Research articles Pegylated interferon review articles Pegylated interferon PubMed articles Pegylated interferon PubMed Central articles Pegylated interferon 2023 articles Pegylated interferon 2024 articles Pegylated interferon Scopus articles Pegylated interferon impact factor journals Pegylated interferon Scopus journals Pegylated interferon PubMed journals Pegylated interferon medical journals Pegylated interferon free journals Pegylated interferon best journals Pegylated interferon top journals Pegylated interferon free medical journals Pegylated interferon famous journals Pegylated interferon Google Scholar indexed journals disease articles disease Research articles disease review articles disease PubMed articles disease PubMed Central articles disease 2023 articles disease 2024 articles disease Scopus articles disease impact factor journals disease Scopus journals disease PubMed journals disease medical journals disease free journals disease best journals disease top journals disease free medical journals disease famous journals disease Google Scholar indexed journals treatment articles treatment Research articles treatment review articles treatment PubMed articles treatment PubMed Central articles treatment 2023 articles treatment 2024 articles treatment Scopus articles treatment impact factor journals treatment Scopus journals treatment PubMed journals treatment medical journals treatment free journals treatment best journals treatment top journals treatment free medical journals treatment famous journals treatment Google Scholar indexed journals CT articles CT Research articles CT review articles CT PubMed articles CT PubMed Central articles CT 2023 articles CT 2024 articles CT Scopus articles CT impact factor journals CT Scopus journals CT PubMed journals CT medical journals CT free journals CT best journals CT top journals CT free medical journals CT famous journals CT Google Scholar indexed journals surgery articles surgery Research articles surgery review articles surgery PubMed articles surgery PubMed Central articles surgery 2023 articles surgery 2024 articles surgery Scopus articles surgery impact factor journals surgery Scopus journals surgery PubMed journals surgery medical journals surgery free journals surgery best journals surgery top journals surgery free medical journals surgery famous journals surgery Google Scholar indexed journals Pathogenesis articles Pathogenesis Research articles Pathogenesis review articles Pathogenesis PubMed articles Pathogenesis PubMed Central articles Pathogenesis 2023 articles Pathogenesis 2024 articles Pathogenesis Scopus articles Pathogenesis impact factor journals Pathogenesis Scopus journals Pathogenesis PubMed journals Pathogenesis medical journals Pathogenesis free journals Pathogenesis best journals Pathogenesis top journals Pathogenesis free medical journals Pathogenesis famous journals Pathogenesis Google Scholar indexed journals Idarucizumab articles Idarucizumab Research articles Idarucizumab review articles Idarucizumab PubMed articles Idarucizumab PubMed Central articles Idarucizumab 2023 articles Idarucizumab 2024 articles Idarucizumab Scopus articles Idarucizumab impact factor journals Idarucizumab Scopus journals Idarucizumab PubMed journals Idarucizumab medical journals Idarucizumab free journals Idarucizumab best journals Idarucizumab top journals Idarucizumab free medical journals Idarucizumab famous journals Idarucizumab Google Scholar indexed journals

Article Details

1. Introduction

Interferon and ribavirin was the therapy for hepatitis c in the past decade [1]. The term Interferon includes interferon alpha, beta and gamma deriving from fibroblasts, epithelial cells, and hepatocytes, plasmacytoid dendritic cells. Interferon-a have two rules: antiviral and immune [2]. Finally interferon create an antiviral status of infected cells stimulating many genes and proteins and inducing the expression of major histocompatibility complex, on antigen-presenting cells and hepatocytes, causing degradation of viral messenger RNA [3-4]. Pegylated interferon is a synthetic interferon modifying pharmacodynamics attaching polyethylene glycol, and its use overtook the interferon to obtain sustained virologic response [5]. Interferon-a can stimulate APCs and enhance humoral autoimmunity, and activate autoreactive T cells. In pathogenesis of autoimmune diseases, viral infection can play a rule in increasing numbers of auoreacitve circulating T cells and B cells, so interferon can trigger autoimmune diseases in patients who have a predisposition. But also iatrogenic interferon has the possible side events such as fever, chills, cardiac insufficiency and immune related disorders associated [3-4].

Autoimmune hepatitis is a liver disease with autoimmune pathogenesis presenting with different clinical picture from subclinical to acute liver failure [6]. It presents the Immunoglobuline G (IgG), anti-nuclear antibody or anti-smooth muscle antibody positivity; and a typical histological finding of interface hepatitis [6-7]. We described a case of autoimmune hepatitis ten years after Hepatitis c treatment.

A 68 year old man was referred to our hospital for increase of serum transaminases (195/480 U/L) at a health checkpoint. Ten years earlier he discovered the HCV infection (genotype1) so he had undergone HCV treatment with peginterferon alpha 2a (180 μg weekly) and ribavirin (1000 mg daily, according to her body weight), he had complete virological response (at 12 weeks of treatment). Before the start of treatment he received hbv vaccine before HCV therapy. He hadn't history of ethanol consume. He is not referred any symptoms, at physical examination: the lungs were clear with no cardiac abnormalities, abdominal tenderness or hepatosplenomegaly. No abdominal ultrasound showed intrahepatic mass, portal hypertension, splenic diameter about 8 cm. Fibroscan: stiffness 8.7 KPa, IQR 2.1

He performed blood examination: leukocytes (6430/µL),AST 423 U/L, ALT 858U/L, total bilirubine 1 (mg/dL), normal plates, AMA negative, ASMA negative, ENA negative, ANA positive 1:160 with pattern rings and rods. Negative serum hepatitis C virus (HCV)-RNA titer was confirmed. Sierologica test for HBV, HCV, HIV remained negative. The patient started steroid therapy (50 mg of deltacortene) according to EASL guideline added azathioprine after 15 days at dosage of 50 mg/day for two week and then at 100 mg/day. At 3 month normalized serum transaminases were observed.

2. Discussion

Interferon has an important action in the immune response of organism to infections through different mechanisms, regulating the antiviral and antiproliferative activity [2-3]. Treatment with interferon alfa can determine the sustained virologic response of HCV in less than 20% of patients. Pegylated interferon is a synthetic interferon modifying pharmacodynamics attaching polyethylene glycol. The treatment with pegylated INF-α, determined sustainable virological response [5].

Interferon-alpha has been studied in various disease conditions and is used as a standard treatment in several of disease. Its use is associated a possible side effects, they have been described in several organ system. Many side-effects involved hematological toxicity, elevated transaminases, nausea, fatigue, and psychiatric sequelae are the most frequently encountered. However the mechanism of side effects remains to be elucidated at the moment [4-5].

The diversity of the described adverse effects may increase because of the high number of patients who receive treatment. Interferon can stimulate the immune system to attacks the patient’s own cell and autoimmune hepatitis is based on attack the patient's own hepatocytes but mechanism of autoimmune hepatitis are still not clarified. In subjects with susceptible genes, which can be induced by the environment, drugs, infection and other factors [6]. HLA is involved in pathogenesis to autoimmune hepatitis, so as the lack of immune tolerance to antigens of hepatocyte that means a lack to response to stimulation of antigenic substances. Autoimmune hepatitis is a chronic hepatitis of unknown etiology, a lot of cytokines have been evolved in its development [7].

It is important know the possible mechanism of damage of interferon to evaluate the patients during and after therapy con interferon and its derivatives.

References

  1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology 60 (2014): 392-420.
  2. Liu Y-J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23 (2005): 275-306.
  3. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284 (1999): 1835-1837.
  4. Kadowaki N, Antonenko S, Lau JY-N, et al. Natural interferon α/β– producing cells link innate and adaptive immunity. J Exp Med 192 (2000): 219-226.
  5. Awad T, Thorlund K, Hauser G. et al. Peginterferon alfa-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 51 (2010): 1176-1184.
  6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol 63 (2015): 971-1004.
  7. Floreani A, Restrepo-Jiménez P, Secchi MF, et al. Etiopathogenesis of autoimmune hepatitis. J Autoimmun 95 (2018): 133-143.

© 2016-2024, Copyrights Fortune Journals. All Rights Reserved